CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen

Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.

starting gate
Biogen plans to start investing more in Leqembi after CMS grants reimbursement • Source: Shutterstock

Eisai Co., Ltd. is taking the early lead on the US commercial effort for Leqembi (lecanemab) in Alzheimer’s disease, but the company’s partner,Biogen, Inc., will add reinforcement – as long as the drug has approval for reimbursement from the Centers for Medicare and Medicaid Services (CMS) following full approval by the US Food and Drug Administration.

“The starting gate is really CMS approval,” Biogen CEO Christopher Viehbacher said during the company’s first quarter sales and earnings...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category